Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2026-02-20 @ 2:22 AM
Study NCT ID:
NCT00910858
Status:
COMPLETED
Last Update Posted:
2013-09-30
First Post:
2009-05-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Sponsor:
Celgene Corporation
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) | View |
Keywords: